Rapport Therapeutics (RAPP) Share-based Compensation (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Share-based Compensation of $72.6 million for Q1 2026, up 1697.03% year-over-year from $4.0 million in Q1 2025, and up 691.98% quarter-over-quarter from -$12.3 million in Q4 2025.
Rapport Therapeutics (RAPP) Share-based Compensation (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Share-based Compensation for 4 consecutive years, with $72.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 1697.03% year-over-year to $72.6 million; the TTM figure through Mar 2026 stood at $72.6 million (up 467.9% YoY), while the FY2025 annual figure was $1.5 million, down 85.34% from the prior year.
- Share-based Compensation grew to $72.6 million in Q1 2026 per RAPP's latest filing, from -$12.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $72.6 million in Q1 2026 and bottomed at -$12.3 million in Q4 2025.
- Historically, Share-based Compensation has averaged $7.2 million across 4 years, with a median of $2.8 million in 2024.
- Annual changes were most pronounced in 2025 — Share-based Compensation plunged 482.29% — and 2026, when it jumped 1697.03%.
- Rapport Therapeutics' Share-based Compensation stood at $998000.0 in 2023, then soared by 221.44% to $3.2 million in 2024, then slumped by 482.29% to -$12.3 million in 2025, then soared by 691.98% to $72.6 million in 2026.
- Business Quant data shows RAPP's Share-based Compensation at $72.6 million in Q1 2026, -$12.3 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.20 Mn |
| Jun 30, 2026 | 7.20 Mn |
| Mar 31, 2026 | 72.60 Mn |
| Mar 31, 2026 | 72.60 Mn |
| Dec 31, 2025 | -12.26 Mn |
| Dec 31, 2025 | -12.26 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 4.39 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.49 Mn |